ClinicalImpactRET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Download All
In this comprehensive online program for pathologists and medical oncologists, gain expert guidance on optimal biomarker testing to identify patients with RET-dependent NSCLC and thyroid cancers and on integration of RET inhibitors into clinical practice. Read expert-authored commentaries, listen to a podcast, or watch an on-demand Webcast archived from a CCO live Webinar followed by downloading the associated slideset.
Joshua Bauml, MD
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Karen L. Reckamp, MD, MS
person default
Lori J. Wirth, MD


Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.

Karen L. Reckamp, MD, MS Released: September 2, 2020

My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.

person default Lori J. Wirth, MD Released: November 4, 2020

Here are my thoughts on what patients need to know about biomarker testing and targeted therapies for lung and thyroid cancers.

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: February 23, 2021

Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.

Joshua Bauml, MD Released: May 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings